Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS

v3.25.2
CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS - USD ($)
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Revenue $ 6,331 $ 156,419 $ 8,561
Cost of revenue 59,398 105,829 9,926
Gross profit (loss) (53,067) 50,590 (1,365)
Operating expenses:      
General and administrative 4,330,028 4,594,743 3,552,055
Research & development 1,779,802 1,561,965 2,179,341
Impairment of intangible asset 0 390,355  
Total operating expenses 6,109,830 6,547,063 5,731,396
Operating loss (6,162,897) (6,496,473) (5,732,761)
Other income (expense):      
Interest expense, net 58,179 (26,878) (15,468)
Other income (expense) (17,183) (215,769) 290,466
Total other income (expense), net (40,996) (242,647) 274,998
Loss before income taxes (6,203,893) (6,739,120) (5,457,763)
Income tax (benefit) (136,661)    
Net loss (6,067,232) (6,739,120) (5,457,763)
Net loss attributable to non-controlling interest (5,985) (5,583) (269)
Net loss attributable to Virax shareholders (6,061,247) (6,733,537) (5,457,494)
Other comprehensive loss:      
Foreign currency adjustment 110,379 (3,639) (111)
Comprehensive loss (5,956,853) (6,735,481) (5,457,652)
Comprehensive loss attributable to non-controlling interest (5,985) (5,583) (269)
Comprehensive loss attributable to Virax $ (5,950,868) $ (6,729,898) $ (5,457,383)
Basic and diluted weighted average shares outstanding      
Ordinary shares 3,730,347 2,006,414 1,062,984
Diluted ordinary shares 3,730,347 2,006,414 1,062,984
Basic and diluted net loss per share to Virax shareholders      
Basic net loss per share - Ordinary shares $ (1.62) $ (3.36) $ (5.13)
Diluted net loss per share - Ordinary shares $ (1.62) $ (3.36) $ (5.13)